Search Results

There are 27998 results for: content related to: Electrocardiographic QTc Changes Due to Moxifloxacin Infusion

  1. Is a Thorough QTc Study Necessary? The Role of Modeling and Simulation in Evaluating the QTc Prolongation Potential of Drugs

    The Journal of Clinical Pharmacology

    Volume 49, Issue 11, November 2009, Pages: 1284–1296, Dr Shashank Rohatagi, Dr Timothy J. Carrothers, Dr Jon Kuwabara-Wagg and Dr Tatiana Khariton

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009341184

  2. Population Pharmacokinetic and Concentration—QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies

    The Journal of Clinical Pharmacology

    Volume 51, Issue 8, August 2011, Pages: 1152–1162, Dr Jeffry A. Florian, Dr Christoffer W. Tornøe, Dr Richard Brundage, Dr Ameeta Parekh and Dr Christine E. Garnett

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270010381498

  3. Creation of a Knowledge Management System for QT Analyses

    The Journal of Clinical Pharmacology

    Volume 51, Issue 7, July 2011, Pages: 1035–1042, Dr Christoffer W. Tornøe, Dr Christine E. Garnett, Dr Yaning Wang, Dr Jeffry Florian, Dr Michael Li and Dr Jogarao V. Gobburu

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270010378408

  4. Effects of Milnacipran on Cardiac Repolarization in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 50, Issue 4, April 2010, Pages: 422–433, Antonia Periclou, Robert H. Palmer, Hongjie Zheng and Charles Lindamood III

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009346059

  5. Characterization of the Human QT Interval: Novel Distribution-Based Assessment of the Repolarization Effects of Moxifloxacin

    The Journal of Clinical Pharmacology

    Volume 52, Issue 8, August 2012, Pages: 1222–1239, Henry H. Holzgrefe, Georg Ferber, Royce Morrison, Olivier Meyer, Andrea Greiter-Wilke and Thomas Singer

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270011409234

  6. Effects of Aliskiren, a Direct Renin Inhibitor, on Cardiac Repolarization and Conduction in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 48, Issue 7, July 2008, Pages: 799–811, Dr Surya Ayalasomayajula, Dr Ching-Ming Yeh, Dr Sujata Vaidyanathan, Mr Brian Flannery, Dr Hans Armin Dieterich, Dr Dan Howard, Dr Martin P. Bedigian and Dr William P. Dole

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270008319330

  7. A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 49, Issue 8, August 2009, Pages: 937–946, Dr Daniel M. Bloomfield, Dr Rajesh Krishna, David Hreniuk, Lisa Hickey, Kalyan Ghosh, Arthur J. Bergman, Jutta Miller, Maria J. Gutierrez, Randall Stoltz, Keith M. Gottesdiener, Gary A. Herman and John A. Wagner

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009337511

  8. Comparison of Maximum Drug Concentration and Area Under the Time-Concentration Curve Between Humans and Animals for Oral and Intravenous Investigational Drugs

    The Journal of Clinical Pharmacology

    Volume 46, Issue 6, June 2006, Pages: 674–692, Dr Tomoe Fujita, Dr Yoshiaki Matsumoto, Machiko Ozaki, Dr Masataka Majima, Dr Yuji Kumagai and Dr Yoshio Ohtani

    Article first published online : 8 MAR 2013, DOI: 10.1177/0091270006287932

  9. Pharmacokinetics and Pharmacodynamics of Three Moxifloxacin Dosage Forms: Implications for Blinding in Active-Controlled Cardiac Repolarization Studies

    The Journal of Clinical Pharmacology

    Volume 50, Issue 11, November 2010, Pages: 1249–1259, Dr Jay W. Mason, Dr Jeffry A. Florian Jr, Dr Christine E. Garnett, Dr Thomas E. Moon, Mr Daniel S. Selness and Mr Randol R. Spaulding

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009356298

  10. Absence of Effect of Telbivudine on Cardiac Repolarization: Results of a Thorough QT/QTc Study in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 49, Issue 12, December 2009, Pages: 1436–1446, Dr Fred Poordad, Dr Gillian Zeldin, Dr Stuart I. Harris, Dr June Ke, Dr Limin Xu, Dr Douglas Mayers and Dr Xiao-Jian Zhou

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009337943

  11. Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes

    The Journal of Clinical Pharmacology

    Volume 49, Issue 11, November 2009, Pages: 1353–1362, Dr Dhruba J. Chatterjee, Dr Naum Khutoryansky, Dr Milan Zdravkovic, Dr Craig R. Sprenger and Dr Jeffrey S. Litwin

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009339189

  12. Comparison of Semiautomated and Fully Automated Methods for QT Measurement During a Thorough QT/QTc Study: Variability and Sample Size Considerations

    The Journal of Clinical Pharmacology

    Volume 49, Issue 8, August 2009, Pages: 905–915, Dr Benoît Tyl, Dr Meriam Kabbaj, Mr Basmah Fassi, Dr Patrick De Jode and Dr William Wheeler

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009337944

  13. Reevaluation of Moxifloxacin Pharmacokinetics and Their Direct Effect on the QT Interval

    The Journal of Clinical Pharmacology

    Volume 52, Issue 3, March 2012, Pages: 329–338, Mr Philippe Grosjean and Dr Saïk Urien

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270011398361

  14. Thorough QT/QTc Study of Ritonavir-Boosted Saquinavir Following Multiple-Dose Administration of Therapeutic and Supratherapeutic Doses in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 52, Issue 4, April 2012, Pages: 520–529, Dr Xiaoping Zhang, Dr Paul Jordan, Ms Laura Cristea, Dr Miklos Salgo, Ms Rana Farha, Mr Stanley Kolis and Dr Lois S. Lee

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270011400071

  15. Evaluation of Eslicarbazepine Acetate on Cardiac Repolarization in a Thorough QT/QTc Study

    The Journal of Clinical Pharmacology

    Volume 52, Issue 2, February 2012, Pages: 222–233, Dr Manuel Vaz-Da-Silva, Dr Teresa Nunes, Dr Luis Almeida, Dr Maria J. Gutierrez, Dr Jeffrey S. Litwin and Dr Patrício Soares-Da-Silva

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270010391789

  16. Lack of Significant Effect of Bilastine Administered at Therapeutic and Supratherapeutic Doses and Concomitantly With Ketoconazole on Ventricular Repolarization: Results of a Thorough QT Study (TQTS) With QT-Concentration Analysis

    The Journal of Clinical Pharmacology

    Volume 52, Issue 6, June 2012, Pages: 893–903, Dr Benoît Tyl, Dr Meriam Kabbaj, Dr Sara Azzam, Dr Ander Sologuren, Dr Román Valiente, Dr Elizabeth Reinbolt, Dr Kathryn Roupe, Ms Nathalie Blanco and Dr William Wheeler

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270011407191

  17. A Supratherapeutic Dose of the Janus Kinase Inhibitor Tasocitinib (CP-690,550) Does Not Prolong QTc Interval in Healthy Participants

    The Journal of Clinical Pharmacology

    Volume 51, Issue 9, September 2011, Pages: 1256–1263, Sriram Krishnaswami, Elizabeth Kudlacz, Rong Wang and Gary Chan

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270010379809

  18. Effects of Standard and Supratherapeutic Doses of Nelfinavir on Cardiac Repolarization: A Thorough QT Study

    The Journal of Clinical Pharmacology

    Volume 49, Issue 3, March 2009, Pages: 291–300, Dr Bharat Damle, Dr Cecilia Fosser, Dr Kaori Ito, Dr Anh Tran, Dr Pamela Clax, Dr Howard Uderman and Dr Paul Glue

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270008329551

  19. Oritavancin, a New Lipoglycopeptide Antibiotic: Results From a Thorough QT Study

    The Journal of Clinical Pharmacology

    Volume 50, Issue 8, August 2010, Pages: 895–903, Dr Borje Darpo, Dr Sun K. Lee, Dr Thomas E. Moon, Dr Nancy Sills and Dr Jay W. Mason

    Article first published online : 7 MAR 2013, DOI: 10.1177/0091270009355449

  20. QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M3 Selective Receptor Antagonist for the Treatment of Overactive Bladder

    The Journal of Clinical Pharmacology

    Volume 45, Issue 9, September 2005, Pages: 1038–1047, Denise B. Serra, Melton B. Affrime, Martin P. Bedigian, Gerard Greig, Slavica Milosavljev, Andrej Skerjanec and Yibin Wang

    Article first published online : 19 MAR 2013, DOI: 10.1177/0091270005279010